Cargando…
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
BACKGROUND: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail. METHODS: Here, we...
Autores principales: | Olesen, Uffe H, Petersen, Jakob G, Garten, Antje, Kiess, Wieland, Yoshino, Jun, Imai, Shin-Ichiro, Christensen, Mette K, Fristrup, Peter, Thougaard, Annemette V, Björkling, Fredrik, Jensen, Peter B, Nielsen, Søren J, Sehested, Maxwell |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019212/ https://www.ncbi.nlm.nih.gov/pubmed/21144000 http://dx.doi.org/10.1186/1471-2407-10-677 |
Ejemplares similares
-
[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts
por: Munk Jensen, Mette, et al.
Publicado: (2013) -
Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors
por: Tanuma, Sei-ichi, et al.
Publicado: (2020) -
Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves’ opthalmopathy
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2016) -
Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans
por: Friebe, D., et al.
Publicado: (2011) -
SIRT1 selectively exerts the metabolic protective effects of hepatocyte nicotinamide phosphoribosyltransferase
por: Higgins, Cassandra B., et al.
Publicado: (2022)